Jin Medical International Ltd. — Cyborg Score 3/10
Challenged
Rehabilitation medical equipment manufacturing
Strategic Profile
The company's Chuzhou manufacturing facility is expected to deliver an annual production capacity of 200,000 units of mid-to-high end electric wheelchairs and senior mobility scooters. 2026–2027 strategic focus includes commercialization after product certifications, manufacturing scale-up, cost normalization, and regional/international expansion. In April 2026, the company regained compliance with Nasdaq's minimum bid price requirement following a 1-for-20 share combination in March 2026.
Cyborg Score Rationale
The company has experienced a total loss to shareholders of 62% over the past three years. The share price has been highly volatile over the past 3 months, moving 16% a week, and the company was unable to file its 20-F by the deadline in January 2026. However, manufacturing expansion and compliance recovery provide execution optionality.
Top Insights
Chuzhou facility projected to launch full capacity production by end of April 2026, targeting 200,000 units annually for electric wheelchairs and mobility scooters
Regained Nasdaq minimum bid price compliance in April 2026 after Class A shares maintained $1.00+ closing bid for 10+ consecutive business days
62% shareholder value loss over three years signals persistent operational or strategic challenges despite manufacturing expansion
Market cap stands at $19.3M as of June 25, 2026, indicating micro-cap scale
Named Competitors
Electric Wheelchairs & Mobility Scooters — Global mobility and seating solutions manufacturer
Mobility Solutions — Leading privately-held mobility device manufacturer
Rehabilitation Equipment — Medical device and healthcare equipment supplier